Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IGIV-SN in Pediatric Primary Humoral Immunodeficiency
NCT03492710Phase 3Withdrawn
- Sponsor
- GC Biopharma
- Start
- Apr 2019
- Primary completion
- Apr 2019
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 3, open-label, single-arm trial of subcuvia in Primary Humoral Immunodeficiency, sponsored by GC Biopharma. Primary endpoints: Incidence of Acute Serious Bacterial Infections at 13 months and Overall Incidence of Adverse Events within 72 hours of infusion. Planned start Apr 2019; status: withdrawn.
02
Drugs
subcuvia
03
Conditions
Primary Humoral Immunodeficiency
Beyond the preview
Go deeper on NCT03492710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03492710.